Clinical trials: Lymphatic Filariasis
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited.
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer
- Trial name
- SkincAIr (NCT07506967)
- Testing
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Where
- 5 sites in Democratic Republic of the Congo, Ethiopia and 3 more
- Volunteers
- 2,420 people
- Sponsor
- Kenya Medical Research Institute
Onchocerciasis
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
The primary purpose of this study was to determine the safety and tolerability of moxidectin in subjects infected with Onchocerca volvulus (a parasitic worm).
- Trial name
- NCT00300768
- Testing
- 2 mg moxidectin, ivermectin 150 mcg/kg, 4 mg moxidectin
- Where
- Ghana
- Volunteers
- 172 people
- Sponsor
- Medicines Development for Global Health
Onchocerciasis, Loiasis
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
This study aims at evaluating the diagnosis performances of the LTS-2 DEC patch for onchocerciasis compared to the gold standard which are the skin snips.
- Conditions
- Onchocerciasis, Loiasis, Diagnoses Disease, Neglected Diseases
- Trial name
- EOLoa (NCT04035174)
- Testing
- LTS-2 DEC patch, Skin snips
- Where
- Cameroon
- Volunteers
- healthy volunteers welcome
- Sponsor
- Center for Research on Filariasis and Other Tropical Diseases, Cameroon
Filariasis
Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside
The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in healthy male caucasian subjects.
- Trial name
- NCT03383614
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Lymphatic Filariasis
Lymphatic Filariasis (LF) in Ivory Coast
The recommended treatment for elimination of LF in sub-Saharan Africa is annual mass drug administration (MDA) with single dose Albendazole (ALB) plus Ivermectin (IVM) given for at least 5-7 years.
- Trial name
- NCT02974049
- Testing
- Albendazole, Ivermectin, Diethylcarbamazine
- Where
- Côte d’Ivoire
- Volunteers
- 189 people
- Sponsor
- University Hospitals Cleveland Medical Center
Lymphatic Filariases
Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis
This study will assess the impact of 2-drug (DA) or 3-drug (IDA) regimens on lymphatic filariasis infection parameters in communities.
- Trial name
- NCT03352206
- Testing
- 2 drug dose - DA, 3 drug dose - IDA
- Where
- 5 sites in Fiji, Haiti and 3 more
- Volunteers
- 20,092 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over.
- Trial name
- NCT03962062
- Testing
- Moxidectin
- Where
- Ghana
- Volunteers
- 36 people
- Sponsor
- Medicines Development for Global Health
Lymphatic Filariasis, Wuchereria Bancrofti Infection
Effect of Albendazole Dose on Clearance of Filarial Worms
This study, conducted in Chennai, India, will determine whether a new treatment regimen of albendazole and diethylcarbamazine for lymphatic filariasis can eliminate the disease more quickly than the standard regimen.
- Trial name
- NCT00375583
- Testing
- DEC/Albendazole
- Where
- India
- Volunteers
- 1,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Onchocerciasis
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in…
- Trial name
- NCT04311671
- Testing
- Moxidectin, Ivermectin, Albendazole
- Where
- 2 sites in Côte d’Ivoire, Democratic Republic of the Congo
- Volunteers
- 12,979 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Podoconiosis
Genetic and Other Aspects of Podoconiosis
Background: Podoconiosis is a disease of the lymph vessels in the legs and feet. It is caused by long-term barefoot exposure to irritant soils, such as those in volcanic areas.
- Trial name
- NCT01939431
- Where
- Ethiopia
- Volunteers
- 76 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Onchocerciasis
Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana
We will examine whether a combination of Ivermectim (IVM) plus Albendazole (ALB) compared to IVM alone given annually, which is the current standard for mass drug administration (MDA), is more effective in sterilizing adult…
- Trial name
- NCT02078024
- Testing
- IVM plus ALB, IVM
- Where
- Ghana
- Volunteers
- 375 people
- Sponsor
- University Hospitals Cleveland Medical Center
Wuchereria Bancrofti Infection
Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)
The study will be an open label cohort study with 2 two-treatment groups 2). Both groups will be treated with a single oral administration of Diethylcarbamazine (DEC) 6 mg/kg + Albendazole (ALB) 400 mg + Ivermectin (IVR) 200…
- Trial name
- NCT02845713
- Testing
- Ivermectin, Diethylcarbamazine Albendazole (IDA)
- Where
- Côte d’Ivoire
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Nodding Syndrome, Epilepsy
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
Background: Childhood epilepsy disorders are particular frequent in the area around Mahenge, southern Tanzania and recent studies have described a novel type of epilepsy with repetitive head nodding episodes and often progressive…
- Conditions
- Nodding Syndrome, Epilepsy, Onchocerciasis, Cognitive Impairment
- Trial name
- NSEC (NCT03653975)
- Testing
- no intervention
- Where
- Tanzania
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Mansonella Perstans Infection, Mp Microfilaremia
Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis
This study will examine: 1) the safety and effectiveness of the drug doxycycline in reducing the number of Mansonella perstans (Mp) worms in the blood of infected patients, and 2) the effects of doxycycline followed by…
- Trial name
- NCT00340691
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Loiasis With Positive Blood Microfilaremia
Assessment and Treatment of Loiasis With Positive Microfilaremia
Loiasis is a vector-borne filariasis endemic in the forested areas in Central Africa whose incidence and morbi-mortality are poorly understood.
- Trial name
- LoPoMi (NCT06194149)
- Volunteers
- 200 people
- Sponsor
- University Hospital, Angers
Malaria, Lymphatic Filariasis
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in…
- Trial name
- RIMDAMAL (NCT02509481)
- Testing
- Ivermectin, Albendazole
- Where
- 2 sites in United States, Burkina Faso
- Volunteers
- 2,712 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Lymphatic Filariasis, Onchocerciasis
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Approximately 5,200 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas.
- Conditions
- Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections
- Trial name
- DOLF-LIBERIA (NCT01905436)
- Testing
- Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
- Where
- Liberia
- Volunteers
- 21,862 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis, Ocular, Loiasis
Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis infection.
- Trial name
- EOLoa (NCT04049630)
- Testing
- LEV 1 mg/kg, LEV 1,5 mg/kg, LEV 2,5 mg/kg
- Where
- Republic of the Congo
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Onchocerciasis, Loiasis
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Onchocerciasis, also known as river blindness, is one of the disease targeted for elimination by the World Health Organization (WHO) in the group of Neglected Tropical Diseases.
- Conditions
- Onchocerciasis, Loiasis, Mansonelliasis, Healthy Volunteers
- Trial name
- Obi1 (NCT06350851)
- Testing
- Biological samples collection (blood drawing + feces)
- Where
- Cameroon
- Volunteers
- 1,128 people, healthy volunteers welcome
- Sponsor
- Bioaster
Lymphatic Filariasis
Research for Elimination of Lymphatic Filariasis (ICIDR)
The purpose of this study is to check blood samples for lymphatic filariasis to determine whether the recent Program to Eliminate Lymphatic Filariasis was successful in controlling lymphatic filariasis in areas of Egypt.
- Trial name
- NCT00406627
- Where
- Egypt
- Volunteers
- 117,500 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine